{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:29:25Z","timestamp":1778088565925,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T00:00:00Z","timestamp":1262649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>This study was performed to compare efficacy and toxicity profiles of paclitaxel using 3\u2010hour versus 96\u2010hour infusion schedules.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients with metastatic breast cancer (MBC) were randomly assigned to receive paclitaxel starting at a dose of 250 mg\/m<jats:sup>2<\/jats:sup> intravenously (iv) over 3 hours every 21 days or paclitaxel starting at a dose of 140 mg\/m<jats:sup>2<\/jats:sup> iv over 96 hours every 21 days. Stratification variables included number of prior chemotherapy regimens and previous response to anthracyclines. Response was assessed every 2 cycles using bidimensional measurements. Patients were allowed to cross over at disease progression or therapy intolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>A total of 214 patients received therapy (107 patients per arm). Response rates were similar: 23.4% in the 3\u2010hour arm and 29.9% in the 96\u2010hour arm (<jats:italic>P<\/jats:italic> = .28). The median duration of response (8.9 months vs 5.7 months; <jats:italic>P<\/jats:italic> = .75) and progression\u2010free survival (5.0 months vs 3.8 months; <jats:italic>P<\/jats:italic> = .17) slightly favored the 96\u2010hour arm. Overall survival was slightly longer in the 3\u2010hour arm (14.2 months vs 12.7 months; <jats:italic>P<\/jats:italic> = .57). One patient who crossed over to the 96\u2010hour arm (N = 18) developed a partial response; no response was noted with crossover to the 3\u2010hour arm (N = 10). Myalgia\/arthralgia and neuropathy were more frequent in the 3\u2010hour arm, whereas mucositis, neutropenic fever\/infection, and diarrhea were more common in the 96\u2010hour arm.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Paclitaxel given by 3\u2010hour or 96\u2010hour infusion was active in MBC. The 96\u2010hour paclitaxel regimen did not significantly improve response or time to disease progression, was more cumbersome to administer, and was associated with greater myelosuppression (but less neuropathy and myalgia) compared with the 3\u2010hour schedule. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24870","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T10:29:33Z","timestamp":1262687373000},"page":"814-821","source":"Crossref","is-referenced-by-count":23,"title":["A randomized phase 2 trial comparing 3\u2010hour versus 96\u2010hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer"],"prefix":"10.1002","volume":"116","author":[{"given":"Stacy L.","family":"Moulder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frankie A.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Thall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Broglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman U.","family":"Buzdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan G.","family":"Arbuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.048"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3403"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685842"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050654"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1621"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1877"},{"key":"e_1_2_7_9_2","volume-title":"Group Sequential Methods With Applications to Clinical Trials","author":"Jennison C","year":"2000"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_11_2","first-page":"163","article-title":"Evaluation of survival data and 2 new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"e_1_2_7_14_2","volume-title":"Modeling Survival Data","author":"Therneau PM","year":"2000"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3353"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.22.4216"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyg075"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089160409000304"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089160208800607"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6699"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"33s","DOI":"10.1200\/jco.2007.25.18_suppl.lba1005","article-title":"Anglo\u2010Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)","volume":"25","author":"Verrill MW","year":"2007","journal-title":"J Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24870","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:25:16Z","timestamp":1760297116000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,5]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,2,15]]}},"alternative-id":["10.1002\/cncr.24870"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24870","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,5]]}}}